<DOC>
	<DOCNO>NCT00289263</DOCNO>
	<brief_summary>This randomize , prospective multicenter phase III study . Two-hundred-sixty-two ( 262 ) patient arm recruit study .</brief_summary>
	<brief_title>Maintenance Chemotherapy Metastatic Breast Cancer</brief_title>
	<detailed_description>The primary objective time disease progression . All patient must treat first line chemotherapy , consist one follow regimen : ) ET ( epirubicin 90 mg/sqm day 1 plus paclitaxel 200 mg/sqm ( 3 hour infusion ) day 1 , b ) AT ( doxorubicin 50 mg/sqm day 1 plus paclitaxel 200 mg/sqm ( 3 hour infusion ) day 2 , administer 3 weekly schedule . Patients complete response , partial response stable disease eligible MANTA1 study . The expected median progression free survival metastatic breast cancer patient achieve disease control first line chemotherapy estimate 10 month . The minimal improvement , justify adoption maintenance paclitaxel , estimate least 3 month . With 262 eligible patient arm , trial power 80 % detect 30 % improvement median progression free survival , test two-sided .05 significance level .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Written inform consent . Patients metastatic breast cancer response stable disease six eight course first line induction chemotherapy treatment Measurable and/or evaluable disease Performance status ECOG 0 , 1 , 2 . Normal cardiac function , confirm leave ventricular ejection fraction ( LVEF ) . Presence peripheral neuropathy &gt; grade 2 NCI Common Toxicity Criteria ( NCICTC ) follow induction chemotherapy Adjuvant taxanebased therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2003</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>maintenance chemotherapy</keyword>
</DOC>